MR001 / Maijiarui Biotech - LARVOL DELTA

A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) (clinicaltrials.gov) - P1/2 | N=42 | Recruiting | Sponsor: Shenzhen Majory Biotechnology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy (clinicaltrials.gov) - P1/2 | N=45 | Recruiting | Sponsor: Shenzhen Majory Biotechnology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma

A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) (clinicaltrials.gov) - P1/2 | N=42 | Not yet recruiting | Sponsor: Shenzhen Majory Biotechnology Co., Ltd. | Trial primary completion date: Oct 2027 ➔ Sep 2028

Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy (clinicaltrials.gov) - P1/2 | N=45 | Not yet recruiting | Sponsor: Shenzhen Majory Biotechnology Co., Ltd.

New P1/2 trial • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma